文献速递系统性红斑狼疮

基因表达谱识别对巴瑞替尼有临床应答的狼疮患者亚群

Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib.
PubMed 文献 · Arthritis Rheumatol · 2026-04-07

该研究对272例SLE患者全血样本进行转录组分析,基于32个免疫相关基因模块的GSVA评分识别出8种分子内型(A-H)。巴瑞替尼的显著临床应答仅限于内型D和G(vs 安慰剂P=0.004和0.048,效应量41.54%和31.89%),基于临床特征的聚类未能识别治疗应答亚群。内型G显示最显著的治疗相关转录调节,干扰素和Treg细胞特征为应答主要预测因子。

要点

  • 基于基因表达谱可识别对巴瑞替尼有应答的SLE分子内型(D和G)。
  • 基于临床特征聚类无法识别巴瑞替尼治疗应答亚群。
  • 干扰素和Treg细胞特征为巴瑞替尼应答的主要预测因子。

核心结论

  • 转录组分析识别出对巴瑞替尼有临床应答的SLE患者亚群,内型D和G显示显著应答。

研究设计与样本

  • 对2期试验中272例SLE患者全血样本进行基线和纵向转录组分析,使用GSVA评估32个免疫相关基因模块。
  • 临床应答采用SLE应答指数-4评估,在安慰剂或巴瑞替尼(2或4 mg每日)治疗24周后判定。

主要发现

  • 基线GSVA评分识别出8种不同分子内型(A-H),免疫紊乱程度逐渐增加。
  • 巴瑞替尼显著临床应答仅限于内型D和G(vs 安慰剂P=0.004和0.048,效应量41.54%和31.89%)。
  • 基于临床特征的患者聚类未能识别治疗应答亚群。
  • 内型G显示最显著的治疗相关转录调节,干扰素、JAK1/JAK2/TYK2信号、免疫蛋白酶体和炎症通路呈剂量依赖性抑制,早至第2周出现并持续至第24周。
  • 内型G中巴瑞替尼的转录变化主要限于临床应答者;特征重要性分析识别干扰素和Treg细胞特征为应答主要预测因子。

关键数值与推荐

  • 临床应答定义为24周后SLE应答指数-4应答。
  • 内型D和G对巴瑞替尼应答的P值分别为0.004和0.048(vs 安慰剂),效应量分别为41.54%和31.89%。

临床怎么用

  • 基因表达谱分型可能有助于筛选对巴瑞替尼更可能应答的SLE患者,内型D和G为潜在优势人群。
  • 干扰素和Treg细胞特征可作为巴瑞替尼应答的预测生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Baricitinib is a JAK1 inhibitor that showed efficacy in patients with systemic lupus erythematosus (SLE) in a phase 2 study but failed to meet the primary endpoint in phase 3 trials. To understand this discrepancy and identify patients with SLE who are responsive to baricitinib, we conducted baseline and longitudinal transcriptomic analysis in patients enrolled in the phase 2 trial. METHODS: Whole-blood samples from 272 patients with SLE were analyzed. Clinical response was assessed using SLE Responder Index-4 after 24 weeks of placebo or baricitinib (2 or 4 mg daily). Gene expression profiling was conducted using Gene Set Variation Analysis (GSVA) of 32 immune-related gene modules. RESULTS: Eight distinct molecular endotypes (A-H) were identified from baseline GSVA scores, with progressively increasing immune disturbances. Baseline demographics were similar across endotypes, with modest but significant differences in anti-double-stranded DNA and complement levels but no SLE Disease Activity Index differences. Significant clinical responses to baricitinib were confined to endotypes D and G (P = 0.004 and 0.048 vs placebo, with effect sizes of 41.54% and 31.89%, respectively). Importantly, patient clustering based on clinical features failed to identify treatment-responsive subsets. Endotype G demonstrated the most pronounced treatment-related transcriptional modulation, with dose-dependent suppression of interferon, JAK1/JAK2/TYK2 signaling, immunoproteasome, and inflammatory pathways evident as early as week 2 and sustained through week 24. Transcriptional changes in response to baricitinib were largely confined to clinical responders in endotype G. Feature importance analysis identified the interferon and Treg cell signatures as major predictors of response. CONCLUSION: Transcriptomic analysis identified subsets of patients with SLE responsive to baricitinib.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bachali P, Grammer A, Lipsky PE, et al. Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib. Arthritis Rheumatol. 2026. PMID: 41870013. doi:10.1002/art.70130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。